The Food and Drug Administration (FDA) recently approved Keytruda (pembrolizumab) plus chemoradiotherapy (CRT) for the treatment of patients with stages 3 to 4A cervical cancer. The first approval of ...
A vaccine combined with Keytruda is associated with a 49% reduction in the risk of recurrence or death. Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results